Tirzepatide became the first approved dual GIP/GLP-1 receptor agonist, demonstrating superior glycemic control and weight-loss outcomes compared with several existing diabetes therapies, creating a new competitive segment within the incretin market In November 2023, Eli Lilly and Company announced that the U.S
Individual trials were analyzed for their quality using the Cochrane Collaborations tool for assessing the risk of bias in randomized trials ( Figure S1 ) ( Statistical Analysis The pooled estimates of the weighted mean differences (WMDs) and 95% CIs for continuous outcomes, including the changes in HbA1c and FPG, as well as the pooled risk ratios (RRs) and their 95% CIs for dichotomous outcomes, including the proportion of participants achieving target HbA1c values and the risk of hypoglycemia, were calculated
Avoid alcoholic beverages or marijuana, as these can increase the effect
There are no long-term contracts, which makes it easier to align treatment with your personal or financial situation
doi:10.1038/s41598-021-87809-4 139
You should follow their advice for a positive health outcome